• Received 6 purchase orders in Q4 FY25, up 18% from FY24
• Receipts from customers reached a record A$5.6m in Q4 FY25
• Positive cash from operations of A$0.4m in Q4 FY25

Curvebeam Ai Ltd, a developer and manufacturer of point-of-care medical imaging equipment, has reported its Appendix 4C and quarterly activity report for the period ended 30 June 2025 (Q4 FY25). Key highlights include:- During Q4 FY25, the company received 6 purchase orders (POs), bringing the total for FY25 to 26 POs, up 18% compared to 22 POs in FY24.- Receipts from customers for Q4 FY25 were a record A$5.6m, up substantially from A$1.5m in Q3 FY25 and A$2.0m in Q4 FY24. This brought receipts from customers for FY25 to A$12.2m, up 72% from A$7.1m in FY24.- Cash from operations for Q4 FY25 was positive A$0.4m, compared to negative A$4.4m in Q3 FY25 and negative A$4.6m in the prior corresponding period.- The company made continued progress on the validation of its HiRise product with a major robotic surgical system vendor, as well as on the development of its bone mineral density (BMD) module, which remains on track for FDA 510(k) clearance in H1 CY26.- Curvebeam AI is in the final stages of securing a A$18 million (€10 million) vendor financing facility with an international partner, which will enable the company to offer leasing options to customers and support direct sales in key markets.

The company expects some positive cash flows outside normal operations for Q1 FY26, including an anticipated A$1.3m in R&D Tax incentive receipts net of loan repayments.